In a recent exploratory phase IIa research.

Amarin announces excellent results from research using Miraxion to take care of unresponsive depression Amarin Corporation today announced positive data analysis from two exploratory phase IIa clinical studies using Miraxion to treat depression fda website . An evaluation of the data from the two studies identifies a significant clinical benefit with Miraxion for a sub-group of patients with specific symptomology. In a recent exploratory phase IIa research, Miraxion was utilized as monotherapy in 77 patients with a new episode of depressive disorder in a six-week trial. In this scholarly study it was prespecified, that the current presence of specific depressive disorder symptomology at the time of entry to the analysis , would predict response.

read more

Steven DeKosky, dean of the University of Virginia medical college, who is not connected to the new research, told the brand new York Times about the spinal tap study. A lot of work needs to be done before the spinal tap check is widely offered to patients. To date, cerebrospinal liquid analyses have not been a routine component of assessment and care for individuals with cognitive impairments and suspected Alzheimer’s disease in the usa, Dr. A. Zara Herskovits, of Brigham and Women’s Hospital, and Dr. John H. Growdon, of Massachusetts General Medical center, wrote in an editorial that accompanied the scholarly study.